RT Journal Article
SR Electronic
T1 Epidemiological and Genomic Analysis of SARS-CoV-2 in Ten Patients from a Mid-sized City outside of Hubei, China in the Early Phase of the COVID-19 Outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20058560
DO 10.1101/2020.04.16.20058560
A1 Jinkun Chen
A1 Evann E. Hilt
A1 Huan Wu
A1 Zhuojing Jiang
A1 QinChao Zhang
A1 JiLing Wang
A1 Yifang Wang
A1 Fan Li
A1 Ziqin Li
A1 Jialiang Tang
A1 Shangxin Yang
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.04.16.20058560.abstract
AB A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing COVID-19 pandemic. In this study, we performed a comprehensive epidemiological and genomic analysis of SARS-CoV-2 genomes from ten patients in Shaoxing (Zhejiang Province), a mid-sized city outside of the epicenter Hubei province, China, during the early stage of the outbreak (late January to early February, 2020). We obtained viral genomes with > 99% coverage and a mean depth of 296X demonstrating that viral genomic analysis is feasible via metagenomics sequencing directly on nasopharyngeal samples with SARS-CoV-2 Real-time PCR Ct values less than 28. We found that a cluster of 4 patients with travel history to Hubei shared the exact same virus with patients from Wuhan, Taiwan, Belgium and Australia, highlighting how quickly this virus spread to the globe. The virus from another cluster of two family members living together without travel history but with a sick contact of a confirmed case from another city outside of Hubei accumulated significantly more mutations (9 SNPs vs average 4 SNPs), suggesting a complex and dynamic nature of this outbreak. Our findings add to the growing knowledge of the epidemiological and genomic characteristics of SARS-CoV-2 and offers a glimpse into the early phase of this viral infection outside of Hubei, China.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that this study received funding from Shaoxing IngeniGen XMK Biotechnologies. The funder had the following involvement with this study: providing sequencing data and preliminary bioinformatics analysis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets and code used for the current study are available from the corresponding author on reasonable request. Example code used for the analysis is available on GitHub. https://github.com/epimath/cm-dag